10 Deals That Shook up the Diagnostics Industry 1

The diagnostics space is rapidly changing and growing. In May, a session on Center Stage at MD&M East will address some of these changes in the in vitro diagnostics market along with fast growth markets and disruptive trends. We have identified 10 of the biggest deals that have really shaken up the IVD and the diagnostics market over the past few years.
 
BioTechne’s Big Play in Liquid Biopsy
BioTechne made moves in the liquid biopsy space when it revealed it would acquire Exosome Diagnostics for $250 million plus $325 million in potential milestones. Waltham, MA-based Exosome has developed the urine-based test ExoDx Prostate (IntelliScore) to assist physicians in determining the need for a prostate biopsy in patients with an ambiguous PSA test result.
 
Quidel Levels Up Big Time
Quidel is a San Diego-based diagnostics company that received quite a change in 2017. The company put up $400 million to buy some of the assets of Alere.  Waltham, MA-based Alere put the assets up for sale to satisfy its merger with Abbott (more on that deal later in the list). Through the transaction, Quidel gained Triage MeterPro products and B-type Naturietic Peptide assays. Quidel said acquiring Alere's triage business and (BNP) assay business could give the company a boost in the point-of-care diagnostics market.
 
Hologic’s Loss, Grifols’ Gain
When Hologic was in the process of trying to acquire Cynosure, it had a problem on its hands. Just what would it do with its stake in its blood screening firm with Grifols. Shortly before the deal occurred, executives from Hologic said the business operated in a challenging market with ongoing headwinds. Hologic ended up divesting its stake in the blood screening business to Grifols for $1.85 billion and moving full stream with Cynosure in the aesthetics health market.
 
Danaher's Big Deal
About three years ago, Danaher expanded its diagnostics offerings significantly through the acquisition of Sunnyvale, CA-based Cepheid. The $4 billion price tag equaled about $53 per share price and marked a 53% premium off Cepheid's closing price (before the deal was announced). Through the acquisition, Danaher gained the full automated GeneXpert systems, among other applications, and products that provide test results for the management of infectious diseases.